key: cord-0906360-mi7t7b6w authors: Biswas, Dr Som Subhro; Awal, Dr Sandeep Singh; Awal, Dr Sampreet Kaur title: COVID-19 and pulmonary tuberculosis – a diagnostic dilemma date: 2021-08-02 journal: Radiol Case Rep DOI: 10.1016/j.radcr.2021.07.079 sha: ed09d5242b1c5a688fc4186baf68c7ff96224b3a doc_id: 906360 cord_uid: mi7t7b6w BACKGROUND: Coronavirus disease 2019 (COVID-19) is an infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Meanwhile, pulmonary tuberculosis(TB) is one of the most common infective lung diseases in developing nations. The concurrence of pulmonary TB and COVID-19 can lead to poor prognosis, owing to the pre-existing lung damage caused by TB. Case presentation: We describe the imaging findings in 3 cases of COVID-19 pneumonia with co-existing pulmonary TB on HRCT thorax. CONCLUSIONS: The concurrence of COVID-19 and pulmonary TB can be a diagnostic dilemma. Correct diagnosis and prompt management is imperative to reduce mortality and morbidity. Hence it is pertinent for imaging departments to identify and report these distinct entities when presenting in conjunction. illness, ranging from mild to severe pneumonia [3, 4] . Patients with pre-existing pulmonary tuberculosis (TB) can have a higher risk of COVID-19 infection [4] . The concurrence of pulmonary TB and COVID-19 can lead to poor prognosis, owing to the pre-existing lung damage caused by TB [4] . India has a high case burden of TB, accounting for a quarter of the TB cases worldwide [4, 5] . Patients with co-existing COVID-19 and pulmonary TB can be a diagnostic challenge [6, 7] . Correct diagnosis and prompt management is imperative to reduce mortality and morbidity caused by the concurrence of pulmonary TB and COVID-19. Hence it is pertinent for imaging departments to identify and report these distinct entities when presenting in conjunction. Computed tomography (CT) of the thorax is a useful aid in detecting and characterizing the lesions of pulmonary TB as well as monitoring late complications [5] . It can correctly diagnose cavitation, bronchiectasis, miliary opacities, lung nodules, fibrotic changes as well as mediastinal and hilar lymphadenopathy [5, 8] . Further, high resolution CT thorax (HRCT thorax) can detect and delineate the extent of ground glass opacities, consolidation and/or fibrosis caused by COVID-19 [3] . We present the imaging findings in COVID-19 with concurrent pulmonary TB in 3 patients without any prior history of mycobacterial pulmonary infection. HRCT Thorax was done using 32 slice Multidetector CT machine using thin sections (1 mm slice thickness). Final diagnosis of pulmonary TB was made by demonstrating acidfast bacilli (AFB) on sputum microscopy, as per the current guidelines [5] . Confirmation of COVID-19 was made based on Reverse transcriptase-polymerase chain reaction (RT-PCR) from nasopharyngeal swab [9] . A 70-year-old male patient presented with fever, chronic cough with exacerbation of symptoms and severe breathlessness since 1 week. Patient also had history of chest pain and few episodes of hemoptysis. On admission, HRCT thorax & RT-PCR for COVID-19 were performed. HRCT thorax revealed multifocal subpleural ground glass opacities with superimposed septal thickening ("crazy paving pattern") in bilateral lung parenchyma, with dorsal and lower lobe predominance (Fig. 1 a) . Chest CT Severity Score was 9 out of 25. Above findings were in favour of atypical pneumonia with CO-RADS (COVID-19 Reporting and Data System) category 5, typical for COVID-19 [10] . Further, fibro-cavitatory changes with cylindrical bronchiectasis involving bilateral upper lobes were seen, more in right upper lobe of lung ( Fig. 1 b,c) . Multiple centrilobular nodules and "tree-in-bud" branching opacities were also noted in right upper lobe and in superior segments of bilateral lower lobes of lung (Fig. 1d) . These features were suspicious for concurrent pulmonary tuberculosis, based on the clinical features and imaging [5, 11] . Reverse transcriptase-polymerase chain reaction (RT-PCR) from nasopharyngeal swab came positive for COVID-19. Furthermore, sputum microscopy revealed acid-fast bacilli (AFB), suggesting pulmonary tuberculosis. Patient was shifted to ICU on day 3 due to worsening dyspnoea. Despite intensive care and oxygen support, patient developed multiorgan dysfunction and succumbed on day 5. Multiple nodular opacities were seen in right upper lobe, some of them showing "treein-bud" appearance ( Fig. 2 c,d) . Fibro-bronchiectatic changes were also seen in this region. Reverse transcriptase-polymerase chain reaction (RT-PCR) for COVID-19 was positive. AFB were revealed on sputum microscopy, suggestive of concurrent TB. Supportive therapy was initiated with oxygen supplementation for management of hypoxemia. Patient was shifted to ICU on day 5 of admission due to deterioration of symptoms, where he was intubated. However, respiratory distress failed to improve, and the patient was declared dead on day 8. HRCT thorax revealed multiple tiny nodular opacities with associated patchy areas of consolidation in bilateral lung parenchyma with upper lobe predominance-more in right upper lobe (Fig. 3a,b,c) . Mild bronchiectatic changes were also noted in right upper lobe (Fig. 3b) . Ill-defined areas of ground glass opacification were seen in bilateral lower lobes (Fig. 3d) . Initial imaging diagnosis on HRCT thorax findings was given as pulmonary TB. Sputum smear microscopy showed acid fast bacilli The 2019 Novel coronavirus disease (COVID-19) is a viral infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1,2]. Meanwhile, pulmonary TB is one of the most common infective lung diseases in developing nations [12] . The concurrence of COVID-19 and pulmonary TB leads to poor outcomes [13] . Certain undiagnosed cases may come to light due to the exacerbation of respiratory symptoms caused by COVID-19. This syndemic of COVID-19 and TB may lead to severe mortality and morbidity, especially in developing nations. Furthermore, patients with pre-existing lung damage due to pulmonary TB show a worse prognosis with COVID-19 pneumonia [14] . Pre-existing lung damage may also predispose patients to COVID-19 leading to further deterioration of patient condition. Such patients with concurrence of COVID-19 and pulmonary TB can pose as a diagnostic dilemma [6] . Correct and timely diagnosis of these two co-existing entities is imperative to reduce the burden of residual fibrosis in patients who survive. CT thorax is an essential imaging modality to identify the key features of both COVID-19 and pulmonary TB [3, 5] . The classical features of pulmonary TB include mediastinal and hilar lymphadenopathy, consolidation, cavitation, pleural effusion and/or pleural thickening and miliary nodules. Findings in chronic and latent tuberculosis are characterized by bronchiectasis, lung fibrosis, fibro-cavitatory changes and ensuing architectural distortion of the lung parenchyma. Centrilobular nodules with "tree-in-bud" branching pattern are commonly seen in association with pulmonary TB [5, 8, 11] . The typical features of COVID-19 pneumonia comprise of bilateral peripheral ground glass opacities and or consolidation, predominantly involving the lower lobes of lung. Bilateral peripheral rounded patchy ground glass opacities may be seen in some cases. Diffuse areas of GGOs may be seen occasionally. In certain patients, GGOs may show upper lobe distribution [3, 15] . Pleural thickening, bronchiectasis, lung nodules, lymphadenopathy and pleural effusion resembling pulmonary TB have also been reported [15] . Furthermore, mechanical ventilation given in cases of severe COVID-19 may incite cavitatory lesions [3, 16] . Real time RT-PCR remains the most common and the current recommended laboratory test for the diagnosis of COVID-19 [17, 18] . Rapid antigen tests may be utilized for detection of SARS-CoV-2 in individuals with high viral load [19] . Increased C-reactive protein (CRP), elevated serum ferritin, reduced white blood cell (WBC) count and lymphopenia, thrombocytopenia is frequently seen in COVID-19 patients and should be closely monitored [20] . Sputum smear microscopy for acid-fast bacilli is the fastest and one of the most indispensable investigations for detection of pulmonary TB [21] . Culture for mycobacteria is further recommended as it has a superior sensitivity than acid-fast staining [21] . Further molecular tests, DNA sequencing techniques, nucleic acid amplification methods may be used to aid diagnosis and identification [21, 22] . The concurrence of COVID-19 and pulmonary TB can be a diagnostic dilemma. Correct diagnosis and prompt management is imperative to reduce mortality and morbidity. Hence it is pertinent for imaging departments to identify and report these distinct entities when presenting in conjunction. All authors read and approved the final manuscript. Patients included in this research gave written informed consent to publish the data & materials contained within this study. The data and materials supporting the findings of this study are available on request from the corresponding author. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding Chest CT in COVID-19: What the Radiologist Needs to Know Tuberculosis in the era of COVID-19 in India Chest tuberculosis: Radiological review and imaging recommendations On tuberculosis and COVID-19 co-infection Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases Imaging in tuberculosis. Cold Spring Harbor perspectives in medicine Diagnosing COVID-19: The Disease and Tools for Detection Bram van Ginneken, Monique Brink, and for the COVID-19 Standardized Reporting Working Group of the Dutch Radiological Society Radiology. CO-RADS: A Categorical CT Assessment Scheme for Patients Suspected of Having COVID-19-Definition and Evaluation Tree-in-Bud Pattern of Pulmonary Tuberculosis on Thin-Section CT: Pathological Implications Tuberculosis: a global health problem A profile of a retrospective cohort of 22 patients of COVID-19 with active/treated tuberculosis Digambar Behera. Tuberculosis, COVID-19, and the End Tuberculosis strategy in India. (2020) Lung India Chest CT features of coronavirus disease 2019 (COVID-19) pneumonia: key points for radiologists Pulmonary cavitation: an underrecognized late complication of severe COVID-19 lung disease Should RT-PCR be considered a gold standard in the diagnosis of COVID-19? Low performance of rapid antigen detection test as frontline testing for COVID-19 diagnosis Evaluation of a SARS-CoV-2 rapid antigen test: Potential to help reduce community spread Diagnosis and treatment of coronavirus disease Mycobacteriosis and Tuberculosis: Laboratory Diagnosis. The open microbiology journal Diagnosing pulmonary tuberculosis with the Xpert MTB/RIF test The authors would like to express their sincere gratitude to Sudeep Singh Awal for his technical guidance, and image editing. The authors would like to express their sincere gratitude to Sudeep Singh Awal for his technical guidance, and image editing. The authors declare that they have no competing interests. Not applicable. The authors read and approved the final manuscript.